The opportunity within the lyophilization services market for biopharmaceuticals is projected to grow at an annualized rate of ~7%, till 2035, claims Roots Analysis

Published: May 2022

Characterized by a rapidly growing pipeline of biosimilars and novel biologics, and the existing challenges associated with lyophilization of biotherapeutics, stakeholders are increasingly relying on service providers offering multidisciplinary expertise in this domain

Roots Analysis has announced the addition of Lyophilization Services Market report to its list of offerings.

In order to achieve longer and commercially viable shelf lives, lyophilization has emerged as the preferred approach, enabling the manufacturing of stable and dry biopharmaceutical formulations. Presently, a number of biopharmaceutical companies are outsourcing their lyophilization operations to contract service providers that have dedicated facilities, equipment and production lines for this purpose. Further, the technological advancements in this domain have resulted in improved productivity and efficiency of the overall process. 

To order this 220+ page report, which features 80+ figures and 140+ tables, please visit

Key Market Insights 

More than 105 companies claim to offer lyophilization services for biopharmaceuticals, globally
Majority (48%) of the industry stakeholders are based in North America, followed by those having headquarters in Europe (42%). In addition, more than 40% of the service providers have the required capabilities to carry out the lyophilization of proteins, followed by companies offering lyophilization services for antibodies (32%) and vaccines (21%).

More than 55% of partnership agreements were inked in 2020 and 2021
Majority of the agreements related to lyophilization of biopharmaceuticals were observed to be instances of acquisitions, representing over 60% of the total partnerships. Further, most of the intercontinental, as well as intracontinental, deals have been inked by players based in North America. 

Expansion activity in this domain has grown at a CAGR of ~28%, between 2018 and 2021 
Around 55% of the initiatives were focused on addition of lyophilization capacity, followed by instances of facility expansions (32%) and new facility additions (14%). More than 85% of the expansions reported in this domain were local initiatives, followed by international initiatives (12%).

North America and Europe are anticipated to capture more than 70% of the market share, by 2035
In addition, the market in Asia Pacific is likely to grow at a relatively faster pace (7.8%), in the long term. Further, in 2035, majority share (52%) of the overall biopharmaceutical lyophilization market is likely to be captured by antibodies. 

You Can Download Free Sample PDF Copy of This Report At:

Key Questions Answered

  • Who are the key players engaged in offering lyophilization services for biopharmaceuticals?
  • What is the relative competitiveness of lyophilization service providers for biopharmaceuticals?
  • What types of partnership models are commonly adopted by stakeholders in this industry?
  • What are the different types of expansion initiatives being undertaken by lyophilization service providers for biopharmaceuticals?
  • What are the key market trends and driving factors that are likely to impact this market?
  • How is the current and future market opportunity likely to be distributed across key segments?

The financial opportunity within the lyophilization services market for biopharmaceuticals has been analyzed across the following segments:

  • Type of Biologic Lyophilized 
  • Antibodies
  • Cell and Gene Therapies
  • Vaccines 
  • Other Biologics
  • Type of Primary Packaging System
  • Vials
  • Syringes
  • Cartridges
  • Ampoules
  • Others
  • Key Geographical Regions 
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and North Africa
  • Rest of the World 

The report also features inputs from eminent industry stakeholders, according to whom, continuous growth of the biological therapeutics pipeline and increasing preference for outsourcing is likely to drive the growth of the overall lyophilization service providers market, in the coming future. The report includes detailed transcripts of discussions held with the following experts:

  • Director of Business Development, and Vice President of Technical Support, Mid-sized Company, US
  • Regional Sales Director, Very Large Company, US
  • Former Director of CMO Business Development, BioDefense Division, Very Large Company, US
  • Head of CDMO Project Management, Small Company, Spain
  • Former Head of Business Development and Marketing, Mid-sized Company, US
  • Commercial DP (Depository Participant) Sales / Group Leader, Very Large Company, South Korea
  • Business Development Manager, Small Company, US
  • Manager, Very Large Company, US
  • Principal Scientist, Very Large Company, US

The research includes profiles of key players (listed below); each profile features a brief overview of the company, its financial performance (if available), recent developments and an informed future outlook.

  • Baxter BioPharma Solutions
  • BioZed Engineering
  • CinnaGen
  • CordenPharma
  • Coriolis Pharma
  • Curia
  • Emergent BioSolutions
  • LSNE Contract Manufacturing
  • Lyophilization Technology 
  • MabPlex
  • Northway Biotech
  • ProJect Pharmaceutics
  • Samsung Biologics 
  • Vetter Pharma
  • WuXi Biologics 

For additional details, please email at 

Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091


  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry